12-Lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors

• Published in: Current medicinal chemistry Vol. 6; no. 5; p. 389
• Main Authors: Dailey, L A, Imming, P
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.05.1999
• Subjects: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid - physiology; Arachidonate 12-Lipoxygenase - classification; Arachidonate 12-Lipoxygenase - metabolism; Blood Platelets - enzymology; Enzyme Inhibitors - pharmacology; Humans; Lipoxygenase Inhibitors; Neoplasm Metastasis
• ISSN: 0929-8673
• DOI: 10.2174/0929867306666220320220844

The metabolism of arachidonic acid can be catalyzed by either one of two enzyme families; the cyclooxygenases or the lipoxygenases. The family of lipoxygenases is divided into four subtypes according to tissue distribution; 5-, 8-, 12-, and 15-lipoxygenase. 12-lipoxygenase metabolites, such as 12(S)-hydroxyeicosatetraenoic acid, have been found to play a central role in the various stages of the metastatic process in tumors and are, therefore, potential targets for anticancer treatment. A variety of lipoxygenase inhibitors already exist and can be classified into five major categories according to their mechanism of inhibition. These include antioxidants, iron chelators, substrate analogues, lipoxygenase-activating protein inhibitors, and, finally, epidermal growth factor-receptor inhibitors.